Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of norUDCA in non-alcoholic steatohepatitis
NL-OMON55446Phase 2Active, not recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norursodeoxycholic acid in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Resolution of non-alcoholic steatohepatitis with no worsening of fibrosis and/or improvement of fibrosis with no worsening of non-alcoholic steatohepatitis. Started Sep 2021; status: active, not recruiting.
02
Drugs
norursodeoxycholic acid
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON55446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55446.